AlphAIalphai — Financial news for AI agents
rttnews.comAUG 211 min read$RNXT

RenovoRx Regains Nasdaq Compliance As Shares Maintain $1 Minimum Bid

RenovoRx (RNXT) regained Nasdaq compliance after its stock maintained a $1 minimum bid for 10 days. The company reported Q2 revenue of $909,000, expanded its cancer center customer base, and completed enrollment in its Phase 3 TIGeR-PaC trial. RNXT stock closed at $1.32, down 3.77% in pre-market trading.

Original reporting
rttnews.com
Published Aug 21, 2026, 2:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 2:40 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$RNXT
Bullish
medium confidence
Mentioned
$RNXT
Relevance
5/10
alphai data visualization · based on rttnews.com
Decision brief

The 30-second read

$RNXTBullishLow
01

Why it matters

Regaining Nasdaq compliance removes a delisting threat, potentially supporting liquidity and investor confidence.

02

Market read

Compliance news is a modest catalyst for RNXT; broader market impact is limited.

03

What to watch

Trial progress and revenue growth could drive longer‑term valuation.

Relevance 5/10Novelty 5/10Timing: pre-market today

Background

RenovoRx is a clinical‑stage biotech developing the RenovoCath device and TIGeR‑PaC trial for pancreatic cancer.

Company-level read

Ticker impact

$RNXTBullishMedium confidence
Context

RenovoRx regained Nasdaq compliance by meeting the $1 minimum bid price for 10 consecutive days.

Expected impact

Potential modest upside as compliance removes delisting risk.

Evidence & confidence

The news removes a regulatory risk factor; no new financial data beyond compliance.

Market effects

Sector

Minimal impact on biotech sector; compliance news is company‑specific.

Regional

No broader regional effect.

Global

Limited to investors in RNXT.

Counterpoint

What could challenge this read

Compliance may be short‑term relief; underlying trial risks remain.

Key entities

  • Company
    RenovoRx

    Biotech firm focused on drug‑delivery devices and cancer trials.

Read at source← All news

Related articles

AUG 14
$RNXTMed

RenovoRx Q2 Earnings Call Highlights

RenovoRx (NASDAQ:RNXT) reported Q2 gross profit of $766,000 and ~84% gross margin. Operating loss was ~$3.4M and net loss per share was $0.06. Cash fell to ~$9.5M at June 30. The company narrowed FY2026 revenue guidance to $3.75M-$4.25M and expects cash-flow break-even in Q4 2027. Phase III TIGeR-PaC enrollment is complete; initial data expected H2 2027.

yahoo.com6 min
AUG 13
$RNXTMedAI 8/10

RenovoRx (RNXT) Q2 2026 Earnings Call Transcript

RenovoRx (RNXT) reported Q2 2026 revenue of $909,000, up 115% year over year, and raised full-year 2026 guidance to $3.75 million to $4.25 million. The company said it completed Phase III TIGeR-PaC enrollment, had 78 survival events vs 86 required, and expects initial results in H2 2027. Cash was $9.5 million at June 30, 2026.

fool.com6 min
AUG 11
$RNXTMed

RenovoRx, Inc.: RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

RenovoRx (Nasdaq: RNXT) said it has completed enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer. Trial enrollment is closing as of Aug. 7, 2026, with completion expected in 1H 2027 after 86 deaths events, and 78 events reported as of Aug. 11. Initial top-line data is expected in 2H 2027; primary endpoint is overall survival.

finanznachrichten.de2 min
MAY 28
$RNXTMedAI 9/10

RenovoRx Says FDA Grants Orphan Drug Status For Oxaliplatin To Treat Pancreatic Cancer

RenovoRx said the FDA granted orphan drug designation for oxaliplatin to treat pancreatic cancer. The company said it is its second such designation in pancreatic cancer and third overall, supporting its RenovoCath targeted intra-arterial delivery approach. RenovoRx previously received ODD for intra-arterial gemcitabine via RenovoCath. In pre-market trading, RNXT was $0.93.

rttnews.com3 min
MAY 28
$RNXTMedAI 9/10

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

RenovoRx (Nasdaq: RNXT) said the FDA granted orphan drug designation for oxaliplatin to treat pancreatic cancer, under Section 526. The company said the designation is its second in pancreatic cancer and third overall, and would provide seven years of market exclusivity plus a 25% tax credit on qualified clinical research and an FDA application fee waiver. RenovoRx is also advancing its Phase III TIGeR-PaC trial and commercializing RenovoCath.

manilatimes.net4 min
MAY 26
$RNXTMedAI 8/10

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

RenovoRx said a Phase III TIGeR-PaC PK/pharmacodynamic sub-study abstract was published for the 2026 ASCO meeting. The study in 16 patients compared intra-arterial gemcitabine via its TAMP/RenovoCath system (IAG) versus IV gemcitabine, reporting lower systemic gemcitabine and higher inactive metabolite levels, with a correlation to reduced CA 19-9. The company expects full enrollment in June 2026 and final readout mid-to-late 2027.

manilatimes.net4 min